Clinical Trial

Trial Protocol ID USOR 24075_BRE 430_EmpowHER-303

Trial Description

A Phase 3, Randomized, Open-Label, Multicenter, Controlled Study To Evaluate The Efficacy And Safety Of Zanidatamab In Combination With Physician’s Choice Chemotherapy Compared To Trastuzumab In Combination With Physician’s Choice Chemotherapy For The Treatment Of Participants With Metastatic HER2-Positive Breast Cancer Who Have Progressed On, Or Are Intolerant To, Previous Trastuzumab Deruxtecan Treatment (EmpowHER-303)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Kashif Ali, MD

Disease Types

Sponsors

  • Jazz Pharma
  • SCRI

ClinicalTrials.gov NCT ID

  • NCT06435429